Leptin-Dependent Regulation of Bone Mass

Osteoporosis, Two-Volume Set

Volumn , Issue , 2008, Pages 1187-1193

  Karsenty, Gerard ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81355158837     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370544-0.50049-5     Document Type: Chapter

References (42)

1. Olsen B.J., Reginato A.M., Wang W. Bone development. Annu Rev Cell Dev Biol 2000, 16:191-220.
2. Karsenty G., Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002, 2:389-406.
3. Corral D.A., Amling M., Priemel M., Loyer E., Fuchs S., Ducy P., Baron R., Karsenty G. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci USA 1998, 95:13835-13840.
4. Spiegelman B.M., Flier J.S. Obesity and the regulation of energy balance. Cell 2001, 104:531-543.
5. Ahima R.S. Body fat, leptin and hypothalamic amenorrhea. N Engl J Med 2004, 351:959-962.
6. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
7. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G.J., Campfield L.A., Clark F.T., Deeds J., et al. Identification and expression cloning of a leptin receptor OB-R. Cell 1995, 83:1263-1271.
8. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., Shen J., Vinson C., Rueger J.M., Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000, 100:197-207.
9. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., Kondo H., Richards W.G., Bannon T.W., Noda M., Clement K., Vaisse C., Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514-520.
10. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L., et al. Serum-immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334:292-295.
11. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., Fei H., Kim S., Lallone R., Ranganathan S., et al. Leptin levels in human and rodent: Measurement of plasma leptin and of RNA in obese and weight-reduced subjects. Nat Med 1995, 1:1155-1161.
12. Bjorbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., Flier J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998, 1:619-625.
13. Caro J.F., Kolaczynski J.W., Nyce M.R., Ohannesian J.P., Opentanova I., Goldman W.H., Lynn R.B., Zhang P.L., Sinha M.K., Considine R.V. Decreased cerebrospinalfluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 1996, 348:159-161.
14. Elefteriou F., Takeda S., Ebihara K., Magre J., Patano N., Kim C.A., Ogawa Y., Liu X., Ware S.M., Craigen W.J., Robert J.J., Vinson C., Nakao K., Capeau J., Karsenty G. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 2004, 101:3258-3263.
15. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
16. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
17. Cornish J., Callon K.E., Bava U., Lin C., Naot D., Hill B.L., Grey A.B., Broom N., Myers D.E., Nicholson G.C., Reid I.R. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002, 175:405-415.
18. Martin A., de Vittoris R., David V., Moraes R., Begeot M., Lafage-Proust M.H., Alexandre C., Vico L., Thomas T. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 2005, 146:3652-3659.
19. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88:131-141.
20. Vaisse C., Clement K., Guy-Grand B., Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998, 20:113-114.
21. Dhillon H., Zigman J.M., Ye C., Lee C.E., McGovern R.A., Tang V., Kenny C.D., Christiansen L.M., White R.D., Edelstein E.A., Coppari R., Balthasar N., Cowley M.A., Chua S., Elmquist J.K., Lowell B.B. Leptin directly activates SF1 neurons in the VMH and this action by leptin is required for normal body-weight homeostasis. Neuron 2006, 49:191-203.
22. Bray G.A., York D.A. The MONA LISA hypothesis in the time of leptin. Recent Prog Horm Res 1998, 53:95-117.
23. Thomas S.A., Palmiter D. Impaired maternal behavior in mice lacking norepinephrine and epinephrine. Cell 1997, 91:583-592.
24. Kurvers H.A. Reflex sympathetic dystrophy: Facts and hypotheses. Vasc Med 1998, 3:207-214.
25. Chruscinski A.J., Rohrer D.K., Schauble E., Desai K.H., Bernstein D., Kobilka B.K. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1999, 274:16694-16700.
26. Fu L., Patel M.S., Bradley A., Wagner E.F., Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 2005, 122:803-815.
27. Schibler U., Naef F. Cellular oscillators: Rhythmic gene expression and metabolism. Curr Opin Cell Biol 2005, 17:223-229.
28. Reppert S.M., Weaver D.R. Coordination of circadian timing in mammals. Nature 2002, 418:935-941.
29. Zheng B., Albrecht U., Kaasik K., Sage M., Lu W., Vaishnav S., Li Q., Sun Z.S., Eichele G., Bradley A., Lee C.C. Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 2001, 105:683-694.
30. Okamura H., Miyake S., Sumi Y., Yamaguchi S., Yasui A., Muijtjens M., Hoeijmakers J.H., van der Horst G.T. Photic induction of mPer1 and mPer2 in cry-deficient mice lacking a biological clock. Science 1999, 286:2531-2534.
31. Jochum W., Passegue E., Wagner E.F. AP-1 in mouse development and tumorigenesis. Oncogene 2001, 20:2401-2412.
32. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H.C., Schinke T., Li L., Brancorsini S., Sassone-Corsi P., Townes T.M., Hanauer A., Karsenty G. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; Implication for Coffin-Lowry syndrome. Cell 2004, 117:387-398.
33. Elefteriou F., Benson M.D., Sowa H., Starbuck M., Liu X., Ron D., Parada L.F., Karsenty G. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 2006, 4:441-451.
34. Elias C.F., Lee C., Kelly J., Aschkenasi C., Ahima R.S., Couceyro P.R., Kuhar M.J., Saper C.B., Elmquist J.K. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 1998, 21:1375-1385.
35. Kristensen P., Judge M.E., Thim L., Ribel U., Christjansen K.N., Wulff B.S., Clausen J.T., Jensen P.B., Madsen O.D., Vrang N., Larsen P.J., Hastrup S. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998, 393:72-76.
36. Ahn J.D., Dubern B., Lubrano-Berthelier C., Clement K., Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in Mc4R deficiency. Endocrinology, 2006, 147:3196-3202.
37. Farooqi I.S., Yeo G.S., Keogh J.M., Aminian S., Jebb S.A., Butler G., Cheetham T., O'Rahilly S. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000, 106:271-279.
38. Guerardel A., Tanko L.B., Boutin P., Christiansen C., Froguel P. Obesity susceptibility CART gene polymorphism contributes to bone remodeling in postmenopausal women. Osteoporos Int 2006, 17:156-157.
39. Rejnmark L., Vestergaard P., Mosekilde L. Treatment with beta-blockers, ACE inhibitors and calcium-channel blockers is associated with a reduced fracture risk: A nationwide case control study. J Hypertens 2006, 24:581-589.
40. Turker S., Karatosun V., Gunal I. Beta-blockers increase bone mineral density. Clin Orthop Relat Res 2006, 443:73-74.
41. Schlienger R.G., Kraenzlin M.E., Jick S.S., Meier C.R. Use of beta-blockers and risk of fractures. JAMA 2004, 292:1326-1332.
42. Pasco J.A., Henry M.J., Sanders K.M., Kotowicz M.A., Seeman E., Nicholson G.C. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004, 19:19-24.